outperform price
ghost ceo play field
readthrough
thesi updat head tool investor skittish given
concern china diagnost slowdown eu potenti
capital-expenditure slowdown think tmo solid organ revenu beat
order calm jitter despit
proven year diversifi busi mix
markedli differ peer still amaz us see roll
peer result case qgen neg pre-a fear
factor possibl macro may pose increment hw
head macro model still show deceler
sequenti acceler bioproduct bioprocess
provid ampl comfort bull growth thesi remain intact
moreov gain share number key end
market provid addit comfort cite
growth bioprocess hsd growth servic busi
proof point final diversifi busi model give protect
one end market soften note teen growth china
biopharma off-set soft electron microscopi busi
highlight portfolio approach benefit capit
deploy perspect find ceo casper comment
healthi pipelin encourag provid anoth
potenti lever support ep posit perspect
head elect year healthcar cost topic
du jour think provid safe port storm investor
along extra day benefit expect
juggernaut pound consist doubl digit earn given
visibl reiter outperform rate share
tweak pt slightli price-to-earnings
consist current level
readthrough think tmo channel busi grew
mid singl digit gener grow
bp market would impli avtr channel busi
grow rang bar extraordinari item impact
think organ print price
share current level would expect potenti
print provid relief share think
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
rais revenu bn bn prior
rais ep
rais prior
mm cork api site acquisit
fx hw mm hw vs mm prior
oper better interest refi share repo advers fx
wors fx impact made better fx off-set impact
tariff mm hw bp hw om
revenu bn midpoint vs evr st bn
vs evr st
ep midpoint vs evr st
 impli msd base exposur growth
industri flat due tough comp
appli msd sd environment piec flat due tough comp
pthn line w/ corp averag rest lp strong
see strong finish year china industri similar happen last year
europ strong high exposur biopharma diagnost region
ad biolog capac patheon st loui manufactur batch mo broke ground
impress turnaround capac build
reinvest debt refi fuel new growth
price in-lin w/ fy expect
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin octob
analyst luke sergott jon bristow vijay kumar primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research report
